AVR

0.00%

$18.00 anteris technologies ltd

AHZ HSV Clinical Trial, page-2

First 2 Last

Share
Profile

Follow
Mr K

1,333 Posts.

311

18/03/15

12:36

Post #: 14934490
Share

Originally posted by thecrabpest ↑

Hi All,

First post here, mostly I just read.

With all of the doom and gloom, just thought I would share some of the the details for the HSV Phase II trials.

I found out about Professor Frazer when the share price was significantly lower than it's highs, and what it is now.

I didn't buy when I first found out about the company, and I wish I did.

I did buy in at 17.5c, then again at 10.5c and again at 9c (unfortunately smaller lots than my initial purchase).

My Average is about 13c. Will I buy more? I don't know, probably not.

Although the news isn't good, I can't help but think about the positive things this company is doing or trying to do.

Cardiocel is literally saving lives whilst providing a better quality of life in that it doesn't cause calcification and the need for remedial surgery.

The HSV vaccine will reduce and hopefully remove some of the shame associated with catching HSV. The HSV vaccine could potentially also save lives in that the stigma and depression related to STIs takes it's toll on people.

Today is one of the days that we can (hopefully) be thankful our children aren't sick in a hospital or we aren't awaiting surgery (hopefully) or our teenagers won't have a doctor tell them that they've just caught something that will be with them for the rest of their life because they didn't practice safe sex.

Today is a tough day, but at the end of the day it "just" money.

-------------------------------------
Trial Details:
-------------------------------------
This is primarily a safety study in patients with ONLY HSV2, so you must reside in Brisbane or SE Queensland to be able to volunteer for the study.

This is essential in case there are side effects which require medical assistance or notification.
In addition, there are up to 22 visits over the year, and some requirements to come for unscheduled visits on occasions.

There are also 3 periods of 45 days where you would need to be a LOCAL resident in proximity to the Q-Pharm Clinic in Herston, Brisbane.

Q-Pharm Pty Ltd in conjunction with Admedus Vaccines Pty Ltd will be conducting a clinical trial to assess the safety and efficacy of a therapeutic HSV-2 DNA vaccine in HSV-2 positive adults after the Easter break:

Thank you for your interest over the last 12 – 18 months, in response to your interest we need generally healthy men and women aged 18 - 50 with:

1. Diagnosis of genital HSV-2 by serology

2. History of recurrent HSV-2 for at least 12 months

3. No history of genital HSV- 1

4. No active treatment or therapy for 7 days prior to dosing

5. Need to perform daily swabs for 45 days prior to dosing

6. Live in Brisbane QLD or surrounding areas approx. 2hrs

7. Must attend multiple visits to Q-Pharm for the next 12 months

8. Must have documentation to show ability to reside / work in Australia

Expand

you sound like one of AHZ employees :\

AHZ Price at posting: 8.5¢ Sentiment: Buy Disclosure: Held
2 Upvote

0 Great analysis

Reply

Top Stories

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

BHP

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

IMM

Immutep reports strong response rate from immunotherapies treating carcinomas

I88

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

NIM

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

SKS

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

AII

Almonty locks in govt agreement for tungsten oxide plant in South Korea

MDI

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

There are more pages in this discussion • 13 more messages in this thread...

First 2 Last

Add AVR (ASX) to my watchlist

(20min delay)
Last $18.00		Change 0.000(0.00%)		Mkt cap ! $346.0M

Open	High	Low	Value	Volume
$18.00	$18.10	$17.70	$58.64K	3.27K

Buyers (Bids)

No.	Vol.	Price($)
1	109	$18.00

Sellers (Offers)

Price($)	Vol.	No.
$18.10	700	1

View Market Depth

No.	Vol.	Price($)
1	48	17.750
1	26	17.650
1	200	17.560
1	500	17.550
1	1	17.510

Price($)	Vol.	No.
18.100	700	1
18.300	150	1
18.500	43	1
18.690	550	1
18.750	143	1

Last trade - 16.10pm 12/07/2024 (20 minute delay)

AVR (ASX) Chart

AHZ HSV Clinical Trial, page-2

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Immutep reports strong response rate from immunotherapies treating carcinomas

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

AHZ HSV Clinical Trial, page-2

Top Stories

Week 28 Wrap: ASX hits all time high; CBA shares' two realities; US inflation hits 3% ahead of China plenum

BHP dips as WA nickel suspended after A$6B hit; losses eased by US CPI and forewarning

Immutep reports strong response rate from immunotherapies treating carcinomas

Infini soars 50% as company reveals it could’ve just made uranium history – redefining what it means to be “high grade”

Nimy to raise $1.21M to explore 'newsy' WA targets

ASX hits all time high out the gate on Friday trades following bullish US inflation data

SKS Technologies wins US$90M award to supply power to international hyperscale data centre in Melbourne

Bitcoin investors need to know the risks

Almonty locks in govt agreement for tungsten oxide plant in South Korea

Nanocap Middle Island Resources kicks off Barkly copper-gold drill run – a potential IOCG-style NT project

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News